Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Mallinckrodt
Medtronic
Baxter
Colorcon

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

Terazosin hydrochloride - Generic Drug Details

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What are the generic drug sources for terazosin hydrochloride and what is the scope of freedom to operate?

Terazosin hydrochloride is the generic ingredient in two branded drugs marketed by Abbott, Apnar Pharma Lp, Beximco Pharms Usa, Heritage Pharma, Hikma, Jubilant Cadista, Mylan, Mylan Technologies, Ranbaxy Labs Ltd, Ivax Sub Teva Pharms, Sandoz, and Teva, and is included in fourteen NDAs. Additional information is available in the individual branded drug profile pages.

There are twenty-four drug master file entries for terazosin hydrochloride. Eighteen suppliers are listed for this compound.

Recent Clinical Trials for terazosin hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Jordan SchultzPhase 1/Phase 2
University of Iowa Institute of Clinical and Translational SciencesPhase 1/Phase 2
Capital Medical UniversityPhase 2

See all terazosin hydrochloride clinical trials

Pharmacology for terazosin hydrochloride
Synonyms for terazosin hydrochloride
(4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl)(tetrahydrofuran-2-yl)methanone hydrochloride
[4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-tetrahydrofuran-2-yl-methanone hydrochloride
[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone hydrochloride
074T088
1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)-piperazine hydrochloride
1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine hydrochloride
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonxyl]piperazine Hydrochloride
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]-piperazine hydrochloride
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]piperazine hydrochloride
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)4-[(tetrahydro-2-furanyl)carbonyl]piperazine hydrochloride
2[4-(Tetrahydro-2-furoy1)piperazinyl]-4-amino-6,7-dimethoxyquinazoline hydrochloride
4-Amino-6,7-dimethoxy-2-[4-(tetrahydro-2-furoyl)-1-piperazinyl]quinazoline Hydrochloride
6,7-dimethoxy-2-[4-(oxolane-2-carbonyl)piperazin-1-yl]quinazolin-4-amine hydrochloride
63074-08-8
63590-64-7 (Parent)
A-45975
AB1009460
AB2000463
Abbott-45975
AC-2074
AC1L2BPY
AK307521
AKOS007930686
AN-14324
BCP12795
C19H25N5O4.HCl
CAS-63074-08-8
CCG-220751
CHEMBL1256665
DB-018541
DS-11401
DSSTox_CID_25493
DSSTox_GSID_45493
DSSTox_RID_80913
DTXSID7045493
EU-0101138
FT-0605647
HMS1570G04
Hytrin
I06-0651
IWSWDOUXSCRCKW-UHFFFAOYSA-N
KS-00000JKM
LP01138
LS-110235
MLS000040261
MLS001077301
MLS001305722
MolPort-003-666-790
NCGC00016026-10
NCGC00016903-01
NCGC00094404-01
NCGC00094404-02
NE45355
NSC-759168
NSC759168
Opera_ID_398
Pharmakon1600-01505576
Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)-, monohydrochloride
Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)-,monohydrochloride
Prestwick_146
s4679
SCHEMBL41545
SMR000044015
SR-01000000197
SR-01000000197-12
SR-01000000197-2
SR-01000000197-4
T 4680
Terazosin HCl
TERAZOSIN HYDROCHLORIDE (anhydrous)
Terazosin hydrochloride anhydrous
Terazosin hydrochloride, >=98% (TLC), powder
Terazosin hydrochloride,pharma
terazosine hydrochloride
Tetrazosin hydrochloride
TL8004930
Tox21_110674
Tox21_110674_1
TR-037527
TRA0127916
V1531
VA11840
Vasocard
Zayasel
Paragraph IV (Patent) Challenges for TERAZOSIN HYDROCHLORIDE
Tradename Dosage Ingredient NDA Submissiondate
HYTRIN TABLET;ORAL terazosin hydrochloride 019057
HYTRIN CAPSULE;ORAL terazosin hydrochloride 020347

US Patents and Regulatory Information for terazosin hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Heritage Pharma TERAZOSIN HYDROCHLORIDE terazosin hydrochloride CAPSULE;ORAL 075614-002 Jan 30, 2001 AB RX No No   Start Trial   Start Trial   Start Trial
Teva TERAZOSIN HYDROCHLORIDE terazosin hydrochloride TABLET;ORAL 074446-004 May 18, 2000 DISCN No No   Start Trial   Start Trial   Start Trial
Heritage Pharma TERAZOSIN HYDROCHLORIDE terazosin hydrochloride CAPSULE;ORAL 075614-003 Jan 30, 2001 AB RX No No   Start Trial   Start Trial   Start Trial
Jubilant Cadista TERAZOSIN HYDROCHLORIDE terazosin hydrochloride CAPSULE;ORAL 075317-004 Dec 20, 2004 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for terazosin hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbott HYTRIN terazosin hydrochloride CAPSULE;ORAL 020347-004 Dec 14, 1994   Start Trial   Start Trial
Abbott HYTRIN terazosin hydrochloride CAPSULE;ORAL 020347-004 Dec 14, 1994   Start Trial   Start Trial
Abbott HYTRIN terazosin hydrochloride CAPSULE;ORAL 020347-002 Dec 14, 1994   Start Trial   Start Trial
Abbott HYTRIN terazosin hydrochloride TABLET;ORAL 019057-001 Aug 7, 1987   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
Baxter
Moodys
McKinsey
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.